Biofilm producers pose a major challenge in treating implant-related orthopedic infections (IROIs). The incidence of IROIs for the closed fracture amounts to 1% to 2% whereas for open fracture it is up to 30%. Due to inappropriate and irrational use of antibiotics in the management of infections, there is an emergence of a global “antimicrobial resistance crisis”. To combat these antimicrobial resistance crises, a few innovative and targeted therapies like nanomedicine, phage therapy, antimicrobial peptides, and sonic therapies have been introduced. In this review, we have detailed the basic mechanisms involved in the employment of bacteriophage therapy for IROIs, along with the preclinical and clinical data on its utility. We also present the guidelines on its regulation, processing, and limitations of bacteriophage therpay to combat the upcoming era of antibiotic resistance.

生物膜生产者在治疗植入物相关骨科感染 (IROI) 方面提出了重大挑战。闭合性骨折的 IROI 发生率为 1% 至 2%，而开放性骨折则高达 30%。由于抗生素在感染管理中的不当和不合理使用，出现了全球性的“抗生素耐药性危机”。为了应对这些抗菌药物耐药性危机，一些创新的靶向疗法被引入，如纳米医学、噬菌体疗法、抗菌肽和声波疗法。在这篇综述中，我们详细介绍了使用噬菌体治疗 IROI 的基本机制，以及其实用性的临床前和临床数据。我们还提出了有关噬菌体疗法的监管、处理和限制的指南，以应对即将到来的抗生素耐药性时代。